Cargando…

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first...

Descripción completa

Detalles Bibliográficos
Autores principales: Bafaloukos, D, Papadimitriou, C, Linardou, H, Aravantinos, G, Papakostas, P, Skarlos, D, Kosmidis, P, Fountzilas, G, Gogas, H, Kalofonos, C, Dimopoulos, A M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409958/
https://www.ncbi.nlm.nih.gov/pubmed/15494721
http://dx.doi.org/10.1038/sj.bjc.6602148
_version_ 1782155910006702080
author Bafaloukos, D
Papadimitriou, C
Linardou, H
Aravantinos, G
Papakostas, P
Skarlos, D
Kosmidis, P
Fountzilas, G
Gogas, H
Kalofonos, C
Dimopoulos, A M
author_facet Bafaloukos, D
Papadimitriou, C
Linardou, H
Aravantinos, G
Papakostas, P
Skarlos, D
Kosmidis, P
Fountzilas, G
Gogas, H
Kalofonos, C
Dimopoulos, A M
author_sort Bafaloukos, D
collection PubMed
description Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m(−2) and paclitaxel 150 mg m(−2), every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3–4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar–plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.
format Text
id pubmed-2409958
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24099582009-09-10 Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group Bafaloukos, D Papadimitriou, C Linardou, H Aravantinos, G Papakostas, P Skarlos, D Kosmidis, P Fountzilas, G Gogas, H Kalofonos, C Dimopoulos, A M Br J Cancer Clinical Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m(−2) and paclitaxel 150 mg m(−2), every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3–4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar–plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS. Nature Publishing Group 2004-11-01 2004-10-19 /pmc/articles/PMC2409958/ /pubmed/15494721 http://dx.doi.org/10.1038/sj.bjc.6602148 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Bafaloukos, D
Papadimitriou, C
Linardou, H
Aravantinos, G
Papakostas, P
Skarlos, D
Kosmidis, P
Fountzilas, G
Gogas, H
Kalofonos, C
Dimopoulos, A M
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title_full Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title_fullStr Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title_full_unstemmed Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title_short Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
title_sort combination of pegylated liposomal doxorubicin (pld) and paclitaxel in patients with advanced soft tissue sarcoma: a phase ii study of the hellenic cooperative oncology group
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409958/
https://www.ncbi.nlm.nih.gov/pubmed/15494721
http://dx.doi.org/10.1038/sj.bjc.6602148
work_keys_str_mv AT bafaloukosd combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT papadimitriouc combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT linardouh combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT aravantinosg combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT papakostasp combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT skarlosd combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT kosmidisp combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT fountzilasg combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT gogash combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT kalofonosc combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup
AT dimopoulosam combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup